Related Experiment Videos
Bone marrow transplantation for chronic myelogenous leukemia
1Royal Postgraduate Medical School, London, UK.
Insights
Bone marrow transplantation offers a high cure rate for chronic phase chronic myelogenous leukemia patients under 50 with matched siblings. Advanced disease and alternative donor options present challenges, but new monitoring techniques show promise.
Area of Science:
- Hematology
- Oncology
- Transplantation Immunology
Background:
- Chronic myelogenous leukemia (CML) in chronic phase (CP) patients under 50 with HLA-identical siblings typically undergo bone marrow transplantation (BMT) within one year of diagnosis.
- Projected disease-free survival for these patients is 70-80% at 4 years, with many achieving a cure.
- BMT outcomes are less favorable for patients with advanced CML.
Purpose of the Study:
- To review current standards and emerging strategies for bone marrow transplantation in chronic myelogenous leukemia.
- To evaluate transplant conditioning regimens, graft-versus-host disease (GVHD) prevention, and donor selection.
- To explore the role of molecular monitoring and autografting in CML treatment.
Main Methods:
- Review of established BMT protocols for CML.
- Comparison of conditioning regimens: cyclophosphamide/total-body irradiation vs. busulphan/cyclophosphamide.
- Assessment of GVHD prophylaxis using cyclosporine and methotrexate.
- Evaluation of polymerase chain reaction (PCR) for monitoring BCR-ABL transcripts.
- Consideration of autografting as an alternative.
Main Results:
- Cyclophosphamide/TBI and busulphan/cyclophosphamide show similar efficacy for conditioning.
- Cyclosporine and methotrexate are optimal for GVHD prevention.
- Non-enlarged spleens do not necessitate splenectomy or radiotherapy.
- "Matched" volunteer marrow donors yield fewer successful outcomes.
- PCR monitoring of BCR-ABL transcripts may identify relapse risk.
- Autografting offers potential for prolonged survival or cure in select patients.
Conclusions:
- Early BMT is crucial for eligible CP CML patients.
- Optimal conditioning and GVHD prophylaxis are established.
- Molecular monitoring and autografting represent important advancements in CML management.
- Further research into alternative donor sources and post-transplant monitoring is warranted.
Abstract:
It is generally accepted that patients with chronic myelogenous leukemia in chronic phase under the age of 50 years who have HLA-identical siblings, should be offered bone marrow transplantation within the first year of diagnosis. The projected disease-free survival for these patients is 70% to 80% at 4 years, and most of these will prove to have been cured. Results of bone marrow transplantation for patients with more advanced disease are less promising. For transplant conditioning there is no important difference between cyclophosphamide plus total-body irradiation and busulphan plus cyclophosphamide. Nonenlarged spleens require neither splenectomy nor additional radiotherapy. The use of cyclosporine and methotrexate is currently the optimal approach to graft-versus-host disease prevention. Fewer good results are obtained with "matched" volunteer marrow donors. Use of the polymerase chain reaction to monitor residual BCR-ABL transcripts after bone marrow transplantation may prove useful in identifying patients at increased risk for relapse. Autografting may offer the prospect of prolonged life or even cure for patients without suitable allogeneic donors.